Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery-Reference-Cited by-同舟云学术

Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery

Published:2022-06 Issue: Volume:40 Page:117-124
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Huebner Nicolai,Rasul Sazan,Baltzer Pascal,Clauser Paola,Hermann Grubmüller Karl,Mitterhauser Markus,Hacker Marcus,Heidenreich Axel,Rajwa Pawel,Fajkovic Harun,Shariat Shahrokh F.,Grubmüller Bernhard

Publisher

Elsevier BV

Subject

Urology

Reference29 articles.

1. (68)Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy;Kopp;World J Urol,2020

2. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact;Grubmüller;Clin Cancer Res,2018

3. The Impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study;Roach;J Nucl Med,2018

4. (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy—diagnostic performance and impact on therapeutic decision-making;Grubmüller;Eur J Nucl Med Mol Imaging,2018

5. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer;Fendler;Clin Cancer Res,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy;BMC Cancer;2024-05-25

2. The current role of precision surgery in oligometastatic prostate cancer;ESMO Open;2022-12